Print

IAVI P001

A Phase I Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Safety and Immunogenicity of TBC-M4, a multigenic MVA HIV Vaccine vs ADVAX, a multigenic DNA HIV Vaccine followed by TBC-M4, a multigenic MVA HIV Vaccine

Trial Details:

I Completed
International AIDS Vaccine Initiative (IAVI), Aaron Diamond AIDS Research Center April 02, 2009
ADVAX,TBC-M4 DNA Nef, Gag, Env, Tat, Pol C; Pox env, gag, tat-rev, and nef-RT C
ADVAX DNA
TBC-M4 Viral Vector - Pox
India 32